Clinical Trial Detail

NCT ID NCT03190213
Title Pembrolizumab for the Treatment of Recurrent High Grade Neuroendocrine Carcinoma (Pembro NEC)
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Utah
Indications

neuroendocrine carcinoma

Therapies

Pembrolizumab

Age Groups: senior adult

No variant requirements are available.